Background/Objectives:This study aims to evaluate the quality of life (QoL) and oncological outcomes in premenopausal women diagnosed with hormone receptor-positive breast cancer who are receiving either bilateral oophorectomy (BO) or gonadotropin-releasing hormone agonist (GnRH) therapy. Both methods serve to inhibit ovarian function, which is essential for the management of estrogen-dependent tumors; however, their effects on QoL have yet to be fully clarified.Methods:Data were analyzed from the Mayo Clinic Breast Disease Registry, focusing on women under 55 diagnosed with estrogen receptor-positive breast cancer who received either BO or GnRH within one year of diagnosis. QoL was assessed using the Patient-Reported Outcomes Measurement Information System Global-10 (PROMIS-10) at baseline and annually for five years.Results:A total of 181 patients were enrolled in the study; 40 into the BO group and 141 to the GnRH group. Both groups exhibited similar levels of sexual dysfunction after a one-year period; however, the BO group stated a higher frequency of hot flashes. PROMIS-10 scores improved in both mental and physical health over time, with no significant differences between the groups. Within the BO group, one recurrence was observed, in contrast to the GnRH group, which had six events. Nonetheless, the difference in recurrence rates did not reach statistical significance.Conclusions:The long-term QoL and oncologic outcomes for premenopausal women with hormone receptor-positive breast cancer were similar for BO and GnRH therapy. These findings emphasize the need for individualized treatment decisions, considering patient preferences and side effects.
背景/目的：本研究旨在评估诊断为激素受体阳性乳腺癌的绝经前女性在接受双侧卵巢切除术（BO）或促性腺激素释放激素激动剂（GnRH）治疗后的生活质量（QoL）及肿瘤学结局。这两种方法均用于抑制卵巢功能，这对雌激素依赖性肿瘤的治疗至关重要；然而，它们对生活质量的影响尚未完全明确。 方法：研究数据来自梅奥诊所乳腺疾病登记库，重点关注55岁以下、诊断为雌激素受体阳性乳腺癌并在确诊后一年内接受BO或GnRH治疗的女性。生活质量通过患者报告结局测量信息系统全球-10（PROMIS-10）在基线和之后五年内每年进行评估。 结果：研究共纳入181例患者；其中40例进入BO组，141例进入GnRH组。两组在一年后均表现出相似程度的性功能障碍；然而，BO组报告潮热的发生频率更高。随着时间的推移，两组患者在PROMIS-10量表中的心理健康和身体健康评分均有所改善，且组间无显著差异。在BO组中观察到1例复发，而GnRH组有6例复发事件。尽管如此，复发率的差异未达到统计学显著性。 结论：对于患有激素受体阳性乳腺癌的绝经前女性，BO与GnRH治疗的长期生活质量和肿瘤学结局相似。这些发现强调，在制定治疗决策时需考虑患者偏好和副作用，进行个体化选择。
肿瘤(癌症)患者之家